Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
View Patent ↗The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.
1. A compound of Formula I:
wherein
X is O;
Y is CO;
R 1 , R 3 , R 4 , R 5 , R 6 , R 8 , and R 9 are each independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;
R 2 is selected from alkoxy, aryloxy, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;
R 7 is selected from aryloxy, alkyl, alkenyl, alkynyl, amide, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;
R 10 is selected from aryloxy, alkenyl, alkyl, alkynyl, amide, amino, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;
each W is independently selected from C and N, wherein if W is N, then p is 0 and if W is C, then p is 1;
at least one W is N;
Z 1 and Z 3 are each a single bond; and
Z 2 is a double bond;
and pharmaceutically acceptable salts thereof.
2. A compound of Formula VII:
wherein:
R 1 , R 2 , R 3 , R 5 , R 6 , R 3 , R 9 , and R 10 are each independently selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone;
R 7 is selected from aryloxy, alkyl, alkenyl, alkynyl, amide, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide and thioketone, or
two adjacent substituents selected from R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are connected in a 5 or 6-membered ring to form a bicyclic aryl or bicyclic heteroaryl;
and pharmaceutically acceptable salts thereof.
3. A compound that is 2-(4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one or a pharmaceutically acceptable salt thereof.
4. A compound according to claim 1 , where R 7 is hydroxyl.
5. A compound according to claim 1 , wherein at least one W in the A ring is N.
6. A compound according to claim 1 , wherein R 5 , R 6 , R 8 , R 9 and R 10 are each hydrogen.
7. A compound according to claim 1 , wherein at least one W in the B ring is N.
8. A compound according to claim 1 , wherein the W in the C ring is selected from N and NR 10 , where R 10 is hydrogen or methyl.
9. A compound according to claim 1 , wherein R 8 is halogen.
10. A compound according to claim 1 , wherein at least one of R 1 , R 2 , R 3 and R 4 is alkoxy.
11. A compound selected from
2-(5-Methoxy-pyridin-2-yl)-chromen-4-one;
2-(5-Hydroxy-pyridin-2-yl)-chromen-4-one;
2-(6-Hydroxy-pyridin-3-yl)-chromen-4-one;
5,7-Dimethoxy-2-(4′-hydroxy-phenyl)-quinolin-4-one;
5,7-Dihydroxy-2-(4-hydroxy-phenyl)-quinolin-4-one;
2-(4-Hydroxy-phenyl)-pyrano[3,2-b]pyridin-4-one;
2-(4-Methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one;
2-(4-Hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one;
2-(4-(2-Hydroxyethoxy)phenyl)-4H-pyrano[2,3-b]pyridine-4-one;
2-(3-Fluoro-4-hydroxyphenyl)pyrano[2,3-b]pyridine-4-one;
2-(4-Hydroxy-3-methylphenyl)-4H-pyrano[2,3-b]pyridine-4-one;
4-(4-Oxo-4H-pyrano[2,3-b]pyridine-2-yl)benzonitrile;
2-(3-Chloro-4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one;
2-(3-Bromo-4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one;
2-(4-Hydroxy-3-methoxyphenyl)-4H-pyrano[2,3-b]pyridine-4-one;
2-(4-Hyd roxy-phenyl)-pyrano[2,3-c]pyridin-4-one;
2-(4-hydroxy-phenyl)-pyrano[3,2-c]pyridin-4-one;
3-(4-Hydroxyphenyl)-2H-isoquinolin-1-one;
3-(3-Fluoro-4-hydroxyphenyl)-5-methoxyisoquinolin-1(2H)-one;
2-Fluoro-4-(5-methoxy-1-(methylamino)-isoquinolin-3-yl)phenol;
6-Naphthalen-2-yl-pyridin-3-ol;
4-Isoquinolin-3-yl-phenol;
4-(1,6-Naphthyridin-7-yl)phenol;
2-(4-Hydroxy-phenyl)-[1,4]naphthoquinone;
2-(4-Hydroxyphenyl)benzo[e][1,3]oxazin-4-one;
6-Naphthalen-2-yl-pyridin-3-ol;
2-(4-Ethoxycarbonyloxy-phenyl)-4-oxo-4H-quinoline-1-carboxylic acid ethyl ester;
4-(4-oxo-4H-pyrano[2,3-b]pyridine-2-yl)phenyl acetate;
4-(Isoquinolin-3-yl)phenyl 2-amino-5-guanidinopentanoate;
4-(1-Oxo-1,2-dihydroisoquinolin-3-yl)phenyl 2-amino-5-guanidinopentanoate;
5,7-Difluoro-2-(4-hydroxy-phenyl)-chromen-4-one;
2-(3,5-Difluoro-4-hydroxyphenyl)chromen-4-one;
2-(4-Hydroxy-3,5-dimethylphenyl)chromen-4-one;
2-(4-Methoxy-phenyl)-thiochromen-4-one;
2-(4-Hydroxy-phenyl)-thiochromen-4-one;
2-(4-Hydroxyphenyl)-3-methyl-4H-chromen-4-one;
4-(6-Bromo-4-oxo-4H-chromen-2-yl)-2-fluorophenyl acetate;
1-(2-Nitro-4-methoxy-phenyl)-chromen-4-one;
2-(4-Hydroxy-2-nitrophenyl)chromen-4-one;
2-(2-Amino-4-methoxy-phenyl)-chromen-4-one;
2-(2-Amino-4-hydroxy-phenyl)-chromen-4-one;
N-[5-Hydroxy-2-(4-oxo-4H-chromen-2-yl)-phenyl]acetamide;
6-Hydroxy-2-(4-hydroxymethylphenyl)chromen-4-one;
2-(2-Fluoro-4-hydroxyphenyl)chromen-4-one;
2-(4-Hydroxyphenyl)-8-nitro-4H-chromen-4-one;
2-(4-Hydroxyphenyl)-8-methoxy-4H-chromen-4-one;
2-(4-Hydroxyphenyl)-5,7-dimethoxy-4H-chromen-4-one;
2-(3-Bromo-4-hydroxyphenyl)-4H-chromen-4-one;
2-(4-Hydroxyphenyl)-4-oxo-4H-chromene-6-carbonitrile;
2-(4-Methoxy-phenyl)-chromen-4-one;
2-(3-Fluoro-4-hydroxyphenyl)chromen-4-one;
2-(4-Hydroxyphenyl)-4-oxo-4H-chromene-6-sulfonic acid;
6-Hydroxymethyl-2-(4-hydroxyphenyl)chromen-4-one;
6-((Dimethylamino)methyl)-2-(4-hydroxyphenyl)-4H-chromen-4-one;
8-Hydroxy-2-(4-hydroxy-phenyl)-chromen-4-one;
2-(4-Hydroxy-phenyl)-chromen-4-one;
7-Hydroxy-2-(4-hydroxy-phenyl)-chromen-4-one;
5-Hydroxy-2-(4-hydroxy-phenyl)-chromen-4-one;
5,7-Dihydroxy-2-(4-hydroxy-phenyl)-chromen-4-one;
5,7-Dihydroxy-2-phenyl-chromen-4-one;
5-Hydroxy-2-phenyl-chromen-4-one;
2-(4-Acetoxy-phenyl)-thiochromen-4-one;
2-(4-Acetoxy-phenyl)-1,1-dioxo-1H-1λ 6 -thiochromen-4-one;
2-(4-Hydroxy-phenyl)-1,1-dioxo-1H-1λ 6 -thiochromen-4-one;
2-(2-(4-Hydroxyphenyl)-4-oxo-4H-chromen-3-yl)acetonitrile;
3-(Hydroxymethyl)-2-(4-hydroxyphenyl)-4H-chromen-4-one;
2-(4-Hydroxyphenyl)-3-(methoxymethyl)-4H-chromen-4-one;
4-Naphthalen-2-yl-phenol;
3-(4-Hydroxyphenyl)-naphthalene-1-ol;
4-(Benzo[b][1,4]dioxin-2-yl)phenyl acetate;
4-(Benzo[b][1,4]dioxin-2-yl)phenol;
4-(4H-Chromen-2-yl)-phenol;
Nicotinic acid 4-(4-oxo-4H-chromen-2-yl)-phenyl ester;
Acetic acid 4-(4-oxo-4H-chromen-2-yl)-phenyl ester;
2-Amino-5-guanidino-pentanoic acid 4-(4-oxo-4H-chromen-2-yl)phenyl ester; and
2-(4-(Nicotinoyloxy)phenyl)-4-oxo-4H-chromene-5,7-diyl dinicotinate,
and pharmaceutically acceptable salts thereof.
12. A pharmaceutical composition comprising a compound according to claim 1 , 2 , or 11 , and a pharmaceutically acceptable carrier.